MoonLake Immunotherapeutics
MLTX
46 hedge funds and large institutions have $122M invested in MoonLake Immunotherapeutics in 2020 Q4 according to their latest regulatory filings, with 46 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
91.44% more ownership
Funds ownership: 0% → 91.44% (+91%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$8.36M |
| 3 |
BlackRock
New York
|
+$7.96M |
| 4 |
RI
RTW Investments
New York
|
+$7.96M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$7.43M |
Top Sellers
MLTX Hedge Fund Activity: Q4 2020 in Review
46 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q4 2020, worth a combined $122M.
Buyers outnumbered sellers: 46 funds opened new MLTX positions and 0 closed out — a net gain of 46 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $10.7M.
- 46 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $122M of MoonLake Immunotherapeutics stock for Q4 2020.
- 46 funds opened new MoonLake Immunotherapeutics positions in Q4 2020 and 0 closed out, a net change of +46 holders.
- The largest MoonLake Immunotherapeutics buyer in Q4 2020 was Adage Capital Partners, an estimated $10.7M added.
Based on aggregated 13F filings for Q4 2020.